参考文献/References:
1 Staunton M, Dodd JD, McCormick PA, et al. Finding evidence-based answers to practical questions in radiology:which patients with inoperable hepatocellular carcinoma will survive longer afte transarterial chemoembolization?. Radiology, 2005, 237(2):404-413.
2 Carr BI. Hepatocellular carcinoma:current management and futuret rends. Gastroenterology, 2004, 127(5 Suppl 1):S218-S224.
3 Berdonosov SS, Berdonosova DG, Znamenskaya NV. Sorption of 90Sr and 90Y with the vaterite modification of calcium carbonate.Radiochemistry, 2003, 45(6):613-615.
4 Ho S, Lau WY, Leung TW, et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med, 1997,24(3):293-298.
5 Wong CY, Salem R, Qing F, et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases:comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med, 2004, 45(11):1892-1897.
6 Salem R, Lewandowski R, Roberts C, et al. Use of Yttrium-90 glass microspheres (Thera-Sphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol, 2004, 15(4):335-345.
7 Cao X, He N, Sun J, et al. Hepatic mdioembolization with Yttrium-90 glass microspheres for treatment of primary liver cancer. Chin Med J (Engl), 1999, 112(5):430-432.
8 Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y microspheres. J Nucl Med, 2000, 41(10):1673-1681.
9 Sarfaraz M, Kennedy AS, Lodge MA, et al. Radiation absorbed dose distribution in a patient treated with yttrium-90 microspheres for hepatocellular carcinoma. Med Phys, 2004, 31(9):2449-2453.
10 Kennedy AS, Nutting C, Coldwell D, et al. Pathologic response and microdosimetry of (90)Y microspheres in man:review of four explanted whole livers. Int J Radiat Oncol Biol Phys, 2004, 60(5):1552-1563.
11 Leung DA, Coin JE, Sickles C, et al. Determinants of postembolization syndrome following hepatic chemoembolization. J Vase Interv Radiol, 2001, 12(3):321-326.
12 Salem R, Thurston KG, Carr BI, et al. Yttrium-90 microspheres:radiation therapy for unresectable liver cancer. J Vasc Interv Radiol, 2002, 13(9 Pt 2):S223-S229.
13 Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microsphere (Thera-Sphere):safety, tumor response, and survival. J Vasc Interv Radiol,2005, 16(12):1627-1639.
14 Ahmad J, Bhee J, Carr BI. The effects of hepatic artery chemotherapy on viral hepatitis in patients with hepatocellular carcinomal. Dig Dis Sic, 2005, 50(2):331-335.
15 Ebied OM, Federle MP, Cart BI, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer, 2003, 97(4):1042-1050.
16 Carr BI-Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma:interim safety and survival data on 65 patients. Liver Transpl, 2004, 10(2 Suppl 1):S107-S110.
17 Geschwind JF, Salem R Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology,2004, 127(Ssupp11):S194-S205.
18 Lee HS, KIm JS, Choi IJ, et al. The safety and efficacy of transcatheter arterial chemcembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. Cancer,1997, 79(11):2087-2094.
相似文献/References:
[1]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[2]张毓艺,姚稚明.18F-FDG PET/CT对非小细胞肺癌淋巴结分期诊断价值的研究进展[J].国际放射医学核医学杂志,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
Zhang Yuyi,Yao Zhiming.The progress of 18F-FDG PET/CT in the diagnosis of N-staging of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
[3]李欢欢,李素平,游金辉.小细胞肺癌伴副肿瘤综合征患者骨显像示肌肉摄取一例[J].国际放射医学核医学杂志,2014,38(2):140.[doi:10.3760/cma.j.issn.1673-4114.2014.02.016]
[4]戈畅,梁硕.化疗联合DC-CIK生物治疗非小细胞肺癌的临床价值及CT灌注成像的疗效评价[J].国际放射医学核医学杂志,2014,38(6):377.[doi:10.3760/cma.j.issn.1673-4114.2014.06.007]
Ge Chang,Liang Shuo.The clinical value and CT perfusion evaluation in chemotherapy combined with DC-CIK biological treatment of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):377.[doi:10.3760/cma.j.issn.1673-4114.2014.06.007]
[5]黄少祥,樊体强.塞来昔布对非小细胞肺癌移植瘤的辐射增敏实验研究[J].国际放射医学核医学杂志,2013,37(3):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
HUANG Shao-xiang,FAN Ti-qiang.Radiosensitization on non-small cell lung cancer induced by celecoxib[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
[6]龙再颖,汤春静,于立明,等.甲状腺乳头状癌术后刺激状态Tg与颈部淋巴结转移关系的研究[J].国际放射医学核医学杂志,2013,37(1):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
LONG Zai-ying,TANG Chun-jing,YU Li-ming,et al.The correlation between the stimulated thyroglobulin level after surgery in papillary thyroid carcinoma and cervical lymph node metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
[7]于丽娟,李迎辞,王文志,等.PET-CT及PET-CT结合Lung VCAR软件对非小细胞肺癌肺门区淋巴结的诊断分析[J].国际放射医学核医学杂志,2012,36(6):323.[doi:10.3760/cma.j.issn.1673-4114.2012.06.002]
YU Li-juan,LI Ying-ci,WANG Wen-zhi,et al.Value of PET-CT and PET-CT combined with Lung VCAR software in the diagnosis of hilar area lymph nodes of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):323.[doi:10.3760/cma.j.issn.1673-4114.2012.06.002]
[8]刘莉,杨景魁.125I粒子植入治疗非小细胞肺癌的护理及辐射防护[J].国际放射医学核医学杂志,2012,36(3):172.[doi:10.3760/cma.j.issn.1673-4114.2012.03.013]
LIU Li,YANG Jing-kui.Radiation protective nursing intervene of 125I seed implantation in non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):172.[doi:10.3760/cma.j.issn.1673-4114.2012.03.013]
[9]朱晓琳,李强.肝腺瘤的影像诊断现状及进展[J].国际放射医学核医学杂志,2011,35(2):124.[doi:10.3760/cma.j.issn.1673-4114.2011.02.014]
ZHU Xiao-lin,LI Qiang.Status and advances in imaging diagnsis of hepatic adenoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):124.[doi:10.3760/cma.j.issn.1673-4114.2011.02.014]
[10]梁吉祥,柴树德,郑广钧,等.CT引导下植入125I粒子治疗非小细胞肺癌切除术后局部复发的疗效[J].国际放射医学核医学杂志,2011,35(3):181.[doi:10.3760/cma.j.issn.1673-4114.2011.03.012]
LIANG Ji-xiang,CHAI Shu-de,ZHENG Guang-jun,et al.CT-guided percutaneous interstitial implantation of 125I for recurrent patients of postoperative non-small cell lung carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):181.[doi:10.3760/cma.j.issn.1673-4114.2011.03.012]
[11]万绪明,许祖闪,侯红军.磁共振表观弥散系数变化率对肝细胞肝癌患者单次TACE术后疗效评价的应用价值[J].国际放射医学核医学杂志,2015,39(2):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
Wan Xuming,Xu Zushan,Hou Hongjun.Applieation value of the change ratio of apparent diffusion coefficient in the therapeutic evaluation of hepatocellular carcinoma treated by single transcatheter arterial chemoembolization[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
[12]王振光,王洋洋.PET/CT显像在肝细胞肝癌诊断中的研究进展[J].国际放射医学核医学杂志,2015,39(2):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
Wang Zhenguang,Wang Yangyang.The development of PET/CT imaging in the diagnosis of hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
[13]张一秋,石洪成.肝细胞癌肿瘤新生血管影像学评价的研究进展[J].国际放射医学核医学杂志,2013,37(1):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
ZHANG Yi-qiu,SHI Hong-cheng.Advances in assessment of imaging examination for tumor neoangiogenesis induced by hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
[14]李红兵,陈勇,曾建国,等.肝动脉化疗性栓塞结合Ⅱ期手术切除治疗巨块型外生型肝癌[J].国际放射医学核医学杂志,2010,34(1):49.[doi:10.3760/cma.j.issn.1673-4114.2010.01.013]
LI Hong-bing,CHEN Yong,ZENG Jian-guo,et al.Treatment of massive extrahepatic growing hepatocellular carcinoma with TACE in combination with secondary resection[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):49.[doi:10.3760/cma.j.issn.1673-4114.2010.01.013]
[15]郑磊,李前伟.18F-氟脱氧葡萄糖PET在原发陛肝细胞癌中的应用[J].国际放射医学核医学杂志,2008,32(1):23.
ZHENG Lei,LI Qian-wei.Application of positron emission tomography with 18F-fluorodeoxyglucose in hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(6):23.
[16]麻广宇,刘家金,徐白萱,等.11C-乙酸盐PET/CT显像在中、高分化肝细胞肝癌复发与转移监测中的应用研究[J].国际放射医学核医学杂志,2018,(4):312.[doi:10.3760/cma.j.issn.1673-4114.2018.04.004]
Ma Guangyu,Liu Jiajin,Xu Baixuan,et al.Application of 11C-acetate PET/CT imaging in the detection of recurrence and metastasis of hepatocellular carcinoma with intermediate and high differentiation[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):312.[doi:10.3760/cma.j.issn.1673-4114.2018.04.004]
[17]赵竞,张占文,马慧,等.PET/CT显像剂18F-氟丙酸在肝癌中的生物学评估[J].国际放射医学核医学杂志,2018,(5):414.[doi:10.3760/cma.j.issn.1673-4114.2018.05.005]
Zhao Jing,Zhang Zhanwen,Ma Hui,et al.Biological evaluation of PET/CT imaging agent 18F-fluoropropionic acid in hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):414.[doi:10.3760/cma.j.issn.1673-4114.2018.05.005]
[18]陈佩和,徐文贵,李小凤,等.肝细胞肝癌的葡萄糖代谢机制及在PET显像中的应用价值[J].国际放射医学核医学杂志,2018,(6):547.[doi:10.3760/cma.j.issn.1673-4114.2018.06.013]
Chen Peihe,Xu Wengui,Li Xiaofeng,et al.Glycometabolism mechanism in hepatocellular carcinoma and its application in PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):547.[doi:10.3760/cma.j.issn.1673-4114.2018.06.013]